ID

16253

Descrizione

A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00192062

collegamento

https://clinicaltrials.gov/show/NCT00192062

Keywords

versioni (1)
  1. 07/07/16 07/07/16 -
Caricato su

7 luglio 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Cancer NCT00192062

Inglese

Eligibility Breast Cancer NCT00192062

1 moduli  
Criteria
Descrizione

Criteria

histological or cytological diagnosis of breast carcinoma with evidence of unresectable, locally recurrent, or metastatic disease. lesions should not be amenable to surgery or radiation of curative intent.
Descrizione

Breast Carcinoma | Unresectable Malignant Neoplasm | Locally Recurrent Malignant Neoplasm | Metastatic Neoplasm | Operative Surgical Procedures Curative | Therapeutic radiology procedure Curative

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0678222
UMLS CUI [2]
C1336869
UMLS CUI [3]
C2986682
UMLS CUI [4]
C2939420
UMLS CUI [5,1]
C0543467
UMLS CUI [5,2]
C1276305
UMLS CUI [6,1]
C1522449
UMLS CUI [6,2]
C1276305
presence of metastatic or local-regional recurrent disease, according to the american joint committee on cancer (greenz, et al, 2002).
Descrizione

Metastatic Neoplasm | Locally Recurrent Malignant Neoplasm | Recurrent tumor regional

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2939420
UMLS CUI [2]
C2986682
UMLS CUI [3,1]
C0521158
UMLS CUI [3,2]
C0205147
uni-dimensionally measurable lesions with clearly defined margin that are clearly measurable by following methods according to computerized tomography (ct), chest x-ray or clinical examination, according to recist criteria (therasse, et al, 2002).
Descrizione

Measurable Disease Linear | Margin Well defined | X-Ray Computed Tomography | chest X-ray | examination; clinical

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C0205132
UMLS CUI [2,1]
C0205284
UMLS CUI [2,2]
C0442825
UMLS CUI [3]
C0040405
UMLS CUI [4]
C0039985
UMLS CUI [5]
C1456356
no prior chemotherapy for metastatic or locoregionally recurrent disease. prior adjuvant or neoadjuvant chemotherapy with anthracyclines based regimen is mandatory. the time from the last dose of prior adjuvant chemotherapy and study entry must be at least 30 days and patients must have completely recovered from all acute chemotherapy related toxicities (with exception of alopecia).
Descrizione

Prior Chemotherapy Metastatic Neoplasm | Prior Chemotherapy Locally Recurrent Malignant Neoplasm | Prior Chemotherapy Recurrent tumor regional | Adjuvant Chemotherapy Anthracyclines | Toxicities Due to Chemotherapy | Patient recovered | Alopecia

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C2939420
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C2986682
UMLS CUI [3,1]
C1514457
UMLS CUI [3,2]
C0521158
UMLS CUI [3,3]
C0205147
UMLS CUI [4,1]
C0085533
UMLS CUI [4,2]
C0282564
UMLS CUI [5,1]
C0600688
UMLS CUI [5,2]
C0678226
UMLS CUI [5,3]
C0392920
UMLS CUI [6]
C1115804
UMLS CUI [7]
C0002170
prior radiotherapy must be completed at least 30 days before study entry.
Descrizione

prior radiation therapy Completed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0205197
no concurrent hormonal therapy for mbc. prior hormonal therapy is allowed, the time from the last dose of prior hormonal therapy for breast cancer to study enrollment must be at least 1 week.
Descrizione

Hormone Therapy Metastatic Breast Cancer

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C0278488
exclusion criteria -
Descrizione

Exclusion Criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0680251
have received treatment within the last 30 days with an investigational drug for any indication before study entry.
Descrizione

Investigational New Drugs | Indication Any

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2,1]
C3146298
UMLS CUI [2,2]
C1552551
concurrent administration of other tumor therapy, including cytotoxic chemotherapy, surgery of cancer, radiotherapy, hormonal therapy and immunotherapy (including herceptin).
Descrizione

cancer treatment | Cytotoxic Chemotherapy | cancer surgery | Therapeutic radiology procedure | Hormone Therapy | Immunotherapy | Herceptin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0677881
UMLS CUI [3]
C0920424
UMLS CUI [4]
C1522449
UMLS CUI [5]
C0279025
UMLS CUI [6]
C0021083
UMLS CUI [7]
C0338204
active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy, unless adequately treated.
Descrizione

Communicable Disease Compliance behavior Limited

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C1321605
UMLS CUI [1,3]
C0439801
pregnancy or breast-feeding.
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
Descrizione

Comorbidity Affecting patient safety | Comorbidity Compliance behavior Limited

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C1113679
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C1321605
UMLS CUI [2,3]
C0439801
Ritorna all'inizio della pagina

Similar models

Eligibility Breast Cancer NCT00192062

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Breast Carcinoma | Unresectable Malignant Neoplasm | Locally Recurrent Malignant Neoplasm | Metastatic Neoplasm | Operative Surgical Procedures Curative | Therapeutic radiology procedure Curative
Item
histological or cytological diagnosis of breast carcinoma with evidence of unresectable, locally recurrent, or metastatic disease. lesions should not be amenable to surgery or radiation of curative intent.
boolean
C0678222 (UMLS CUI [1])
C1336869 (UMLS CUI [2])
C2986682 (UMLS CUI [3])
C2939420 (UMLS CUI [4])
C0543467 (UMLS CUI [5,1])
C1276305 (UMLS CUI [5,2])
C1522449 (UMLS CUI [6,1])
C1276305 (UMLS CUI [6,2])
Metastatic Neoplasm | Locally Recurrent Malignant Neoplasm | Recurrent tumor regional
Item
presence of metastatic or local-regional recurrent disease, according to the american joint committee on cancer (greenz, et al, 2002).
boolean
C2939420 (UMLS CUI [1])
C2986682 (UMLS CUI [2])
C0521158 (UMLS CUI [3,1])
C0205147 (UMLS CUI [3,2])
Measurable Disease Linear | Margin Well defined | X-Ray Computed Tomography | chest X-ray | examination; clinical
Item
uni-dimensionally measurable lesions with clearly defined margin that are clearly measurable by following methods according to computerized tomography (ct), chest x-ray or clinical examination, according to recist criteria (therasse, et al, 2002).
boolean
C1513041 (UMLS CUI [1,1])
C0205132 (UMLS CUI [1,2])
C0205284 (UMLS CUI [2,1])
C0442825 (UMLS CUI [2,2])
C0040405 (UMLS CUI [3])
C0039985 (UMLS CUI [4])
C1456356 (UMLS CUI [5])
Prior Chemotherapy Metastatic Neoplasm | Prior Chemotherapy Locally Recurrent Malignant Neoplasm | Prior Chemotherapy Recurrent tumor regional | Adjuvant Chemotherapy Anthracyclines | Toxicities Due to Chemotherapy | Patient recovered | Alopecia
Item
no prior chemotherapy for metastatic or locoregionally recurrent disease. prior adjuvant or neoadjuvant chemotherapy with anthracyclines based regimen is mandatory. the time from the last dose of prior adjuvant chemotherapy and study entry must be at least 30 days and patients must have completely recovered from all acute chemotherapy related toxicities (with exception of alopecia).
boolean
C1514457 (UMLS CUI [1,1])
C2939420 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C2986682 (UMLS CUI [2,2])
C1514457 (UMLS CUI [3,1])
C0521158 (UMLS CUI [3,2])
C0205147 (UMLS CUI [3,3])
C0085533 (UMLS CUI [4,1])
C0282564 (UMLS CUI [4,2])
C0600688 (UMLS CUI [5,1])
C0678226 (UMLS CUI [5,2])
C0392920 (UMLS CUI [5,3])
C1115804 (UMLS CUI [6])
C0002170 (UMLS CUI [7])
prior radiation therapy Completed
Item
prior radiotherapy must be completed at least 30 days before study entry.
boolean
C0279134 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
Hormone Therapy Metastatic Breast Cancer
Item
no concurrent hormonal therapy for mbc. prior hormonal therapy is allowed, the time from the last dose of prior hormonal therapy for breast cancer to study enrollment must be at least 1 week.
boolean
C0279025 (UMLS CUI [1,1])
C0278488 (UMLS CUI [1,2])
Exclusion Criteria
Item
exclusion criteria -
boolean
C0680251 (UMLS CUI [1])
Investigational New Drugs | Indication Any
Item
have received treatment within the last 30 days with an investigational drug for any indication before study entry.
boolean
C0013230 (UMLS CUI [1])
C3146298 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
cancer treatment | Cytotoxic Chemotherapy | cancer surgery | Therapeutic radiology procedure | Hormone Therapy | Immunotherapy | Herceptin
Item
concurrent administration of other tumor therapy, including cytotoxic chemotherapy, surgery of cancer, radiotherapy, hormonal therapy and immunotherapy (including herceptin).
boolean
C0920425 (UMLS CUI [1])
C0677881 (UMLS CUI [2])
C0920424 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
C0279025 (UMLS CUI [5])
C0021083 (UMLS CUI [6])
C0338204 (UMLS CUI [7])
Communicable Disease Compliance behavior Limited
Item
active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy, unless adequately treated.
boolean
C0009450 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
pregnancy or breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Comorbidity Affecting patient safety | Comorbidity Compliance behavior Limited
Item
serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C1321605 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial